STAAR Surgical (NASDAQ:STAA) Misses Q4 CY2025 Sales Expectations, Stock Drops 11.2%

Medical lens company STAAR Surgical (NASDAQ:STAA) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 18.1% year on year to $57.8 million. Its GAAP loss of $0.37 per share was significantly below analysts’ consensus estimates.
Nasdaq

First Week of STAA October 21st Options Trading

Investors in Staar Surgical Co. (Symbol: STAA) saw new options begin trading this week, for the October 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the STAA options chain for the new October 21st contracts and ...
Insider Monkey

STAAR Surgical Company (STAA): A Bull Case Theory

We came across a bullish thesis on STAAR Surgical Company on Yet Another Value Blog’s Substack. In this article, we will summarize the bulls’ thesis on STAA. STAAR Surgical Company’s share was trading at $19.15 as of January 28th. STAA’s ...

Assessing STAAR Surgical (STAA) Valuation As Investor Interest Returns After Recent Share Price Momentum

Why STAAR Surgical Is Back On Investor Radars STAAR Surgical (STAA) has drawn fresh attention after recent trading, with the share price at $19.90 and performance mixed over the past month and past 3 months.
Benzinga.com

Eye Lens Maker STAAR Surgical Expects Q1 Sales To Beat Consensus

$5 million represents STAAR's highest quarterly ICL sales in U.S. since it obtained FDA approval for EVO ICL in March 2022. Analyst says achieving STAAR Surgical's revenue target for 2026 seems challenging, especially considering the necessary acceleration.
Nasdaq

Notable Tuesday Option Activity: SITE, FIVE, STAA

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in SiteOne Landscape Supply Inc (Symbol: SITE), where a total of 5,117 contracts have traded so far, representing approximately 511,700 underlying shares.